Bill & Melinda Gates Foundation

United Statesgatesfoundation.org

The Bill & Melinda Gates Foundation is a private philanthropic organization headquartered in Seattle, Washington, established in 2000. It provides grants and program-related investments to support global health, development, and education, working with public, academic, and industry partners worldwide.

Relevant to the chemical and process industries, the foundation funds R&D and scale-up for technologies including vaccines and biologics manufacturing, drug delivery and formulation, diagnostic chemistry, vector control (such as insecticide-treated nets), sanitation and water treatment systems, and agricultural science and biotechnology. Its programs often focus on translating lab-scale innovations into affordable, quality-assured products for low- and middle-income markets, supporting clinical validation, regulatory pathways, quality systems, and distributed manufacturing capacity.

The foundation collaborates with universities, startups, established companies, and multilateral organizations through grants, advance market commitments, and other financing tools to accelerate access to health and agricultural technologies.

Latest news on Gates Foundation

24 September 2026
EIB and European Commission back VaxThera vaccine facility in Colombia

€15m first tranche of a €35m package to expand a Colombian plant to produce up to 250m doses annually, plus a €1.5m R&D grant for three vaccine candidates.

24 July 2026
Merck outlines LMIC access plans for alimatravir with 129‑country voluntary licenses

Early, multi-faceted plan includes seven royalty‑free licenses covering 129 LMICs, regional manufacturing support in Africa and Latin America, and early manufacturing investment to speed availability.

15 July 2026
Merck to present daily, weekly and monthly HIV data at AIDS 2026

Late‑breakers include Week 48 results for once‑weekly islatravir+lenacapavir and Week 24 data for islatravir+ulonivirine; once‑monthly PrEP trials are enrolling.

16 April 2026
EIB, EC and IFC back Biovac to build Africa’s first end-to-end vaccine manufacturing plant

€75M quasi‑equity and $20M senior loan finance a South African end‑to‑end multi‑vaccine plant (2028) to produce cholera, polio, pneumonia and meningitis vaccines (30–40M doses/yr); 340 skilled, 7,000 indirect jobs.

22 September 2025
Topsoe Advances CO2-to-Food Project to Next Phase

A consortium progresses to phase two, optimizing CO2-to-food tech with renewed funding, aiming to create sustainable protein alternatives amid global hunger challenges.